Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)

Schuhmacher, Alexander; Hinder, Markus; Brief, Elazar; Gassmann, Oliver; Hartl, Dominik

dc.contributor.author	Hartl, Dominik
dc.date.accessioned	2026-02-27T09:29:26Z
dc.date.available	2026-02-27T09:29:26Z
dc.date.issued	2025
dc.identifier.issn	1359-6446
dc.identifier.uri	http://hdl.handle.net/10900/176185
dc.language.iso	en	en
dc.publisher	London : Elsevier Sci Ltd	de_DE
dc.relation.uri	http://dx.doi.org/10.1016/j.drudis.2025.104291
dc.subject.ddc	610	de_DE
dc.title	Benchmarking R&D success rates of leading pharmaceutical companies: an empirical analysis of FDA approvals (2006-2022)	de_DE
dc.type	Article	de_DE
utue.quellen.id	20250630000000_02070
utue.personen.roh	Schuhmacher, Alexander
utue.personen.roh	Hinder, Markus
utue.personen.roh	Brief, Elazar
utue.personen.roh	Gassmann, Oliver
utue.personen.roh	Hartl, Dominik
dcterms.isPartOf.ZSTitelID	Drug Discovery Today	de_DE
dcterms.isPartOf.ZS-Issue	2	de_DE
dcterms.isPartOf.ZS-Volume	30	de_DE
utue.fakultaet	Universität Tübingen (ohne Fakultätsangabe)